In this episode of Talking Life Science, Ivan Orban, Senior Teamleader at the Aristo Group in Austria, speaks with Mateo de Bardeci, Co-Founder of DeepPsy, about one of the major challenges in modern psychiatry: the fact that depression treatment is still largely based on trial and error, and how data and neuroscience can help improve treatment decisions.

Mateo explains how DeepPsy analyses EEG and ECG data from patients with depression to support psychiatrists in choosing between already approved treatment options. By providing additional insights derived from brain signal patterns, the company aims to shorten the trial-and-error process that is common in depression treatment.

The conversation also addresses the potential benefits of this approach, including reducing unnecessary treatment changes, avoiding side effects and improving efficiency in clinical decision-making for both patients and physicians.

In addition, Mateo shares insights into the regulatory journey of DeepPsy, including certifications in Switzerland and the UK, plans for EU certification, and collaborations with clinics and hospitals. He reflects on founding a medical device startup, the challenges of regulation and quality management, and the importance of maintaining a clear long-term vision when building a company in the life sciences sector.

Host: Ivan Orban, Senior Teamleader Aristo Group

Guest: Mateo de Bardeci, Co-Founder DeepPsy